一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> ACS Materials Letters >>article
ACS Materials Letters

ACS Materials Letters

IF: 9.59
Download PDF

Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review.

Published:4 December 2018 DOI: 10.7326/M18-1523 PMID: 30383133
Angela Lowenstern, Sana M Al-Khatib, Lauren Sharan, Ranee Chatterjee, Nancy M Allen LaPointe, Bimal Shah, Ethan D Borre, Giselle Raitz, Adam Goode, Roshini Yapa, J Kelly Davis, Kathryn Lallinger, Robyn Schmidt, Andrzej S Kosinski, Gillian D Sanders

Abstract

Background: The comparative safety and effectiveness of treatments to prevent thromboembolic complications in atrial fibrillation (AF) remain uncertain.

Purpose: To compare the effectiveness of medical and procedural therapies in preventing thromboembolic events and bleeding complications in adults with nonvalvular AF.

Data sources: English-language studies in several databases from 1 January 2000 to 14 February 2018.

Study selection: Two reviewers independently screened citations to identify comparative studies of treatments to prevent stroke in adults with nonvalvular AF who reported thromboembolic or bleeding complications.

Data extraction: Two reviewers independently abstracted data, assessed study quality and applicability, and rated strength of evidence.

Data synthesis: Data from 220 articles were included. Dabigatran and apixaban were superior and rivaroxaban and edoxaban were similar to warfarin in preventing stroke or systemic embolism. Apixaban and edoxaban were superior and rivaroxaban and dabigatran were similar to warfarin in reducing the risk for major bleeding. Treatment effects with dabigatran were similar in patients with renal dysfunction (interaction P > 0.05), and patients younger than 75 years had lower bleeding rates with dabigatran (interaction P < 0.001). The benefit of treatment with apixaban was consistent in many subgroups, including those with renal impairment, diabetes, and prior stroke (interaction P > 0.05 for all). The greatest bleeding risk reduction was observed in patients with a glomerular filtration rate less than 50 mL/min/1.73 m2 (P?= 0.003). Similar treatment effects were observed for rivaroxaban and edoxaban in patients with prior stroke, diabetes, or heart failure (interaction P > 0.05 for all).

Limitation: Heterogeneous study populations, interventions, and outcomes.

Conclusion: The available direct-acting oral anticoagulants (DOACs) are at least as effective and safe as warfarin for patients with nonvalvular AF. The DOACs had similar benefits across several patient subgroups and seemed safe and efficacious for a wide range of patients with nonvalvular AF.

Primary funding source: Patient-Centered Outcomes Research Institute. (PROSPERO: CRD42017069999).

Substances (5)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Rivaroxaban 366789-02-8 C19H18ClN3O5S 1016 suppliers $5.00-$3515.00
Apixaban 503612-47-3 C25H25N5O4 894 suppliers $5.00-$3036.00
Dabigatran 211914-51-1 C25H25N7O3 319 suppliers $8.00-$3176.25
edoxaban 480449-70-5 C24H30ClN7O4S 277 suppliers $8.00-$24139.50
Warfarin 81-81-2 C19H16O4 227 suppliers $19.00-$2055.90

Similar articles

IF:3.2

Roxadustat for Patients with Post-transplant Anemia: A Narrative Review

Kidney Diseases Xiaoxiao Tang, Fei Liu,etc Published: 10 November 2023
青海省| 黄陵县| 四子王旗| 神木县| 大英县| 科尔| 彩票| 潢川县| 秦皇岛市| 潼南县| 温宿县| 穆棱市| 田东县| 岗巴县| 肃宁县| 巴彦县| 襄城县| 嘉禾县| 姚安县| 彭水| 沂南县| 綦江县| 苍溪县| 东莞市| 张家界市| 福海县| 独山县| 阳谷县| 高邑县| 大姚县| 十堰市| 寿阳县| 峨眉山市| 筠连县| 阿城市| 繁峙县| 清新县| 庆阳市| 宿州市| 伽师县| 安泽县|